HireQuest (HQI) submitted a proposal to acquire all of the outstanding shares of common stock of TrueBlue (TBI) for $7.50 per share. The consideration would

TherapeuticsMD (TXMD) announced it continues to evaluate a variety of strategic alternatives that may include, but not be limited to, an acquisition, merger, other business

The Financial Times reported that BP’s (BP) rivals are weighing the opportunity to buy the UK energy major at a steep discount. Listed companies Shell

Vor Bio (VOR) announced that the Board has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both

Geely submitted a non-binding proposal to take ZEEKR (ZK) private by acquiring all of the issued and outstanding shares and American Depositary Shares (ADSs) of

Green Dot (GDOT) has drawn interest from private equity firms, with some forming consortia to pursue a potential acquisition, Bloomberg reported, citing Fortune. Strategic buyers

Reuters reported that WiseTech Global, one of Australia’s top-listed tech firms, confirmed that it is participating in a strategic review of U.S.-based cloud logistics company

Zeta Global (ZETA) has recently attracted significant takeover interest, CEO David Steinberg said during an earnings call. “I’ve been spending a disproportionate percentage of my

LiveOne (LVO), an online music and entertainment company, announced that it is exploring strategic options. CEO Robert Ellin said that “in evaluating the market landscape,

EuroHoldings (EHLD) announced that its Board has initiated a comprehensive review of strategic alternatives to maximize shareholder value. These alternatives include, among other possibilities, a

Bloomberg reported that restaurant software provider Olo (OLO) is exploring a potential sale after attracting takeover interest. Olo, which counts restaurateur Danny Meyer and The

Cellectar Biosciences (CLRB) announced that the company will explore a full range of strategic alternatives to advance its promising platform and radiopharmaceutical drug development pipeline